alemtuzumab

Known as: MoAb CD52, Anti-CD52 Monoclonal Antibody, alemtuzumab [Chemical/Ingredient] 
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2017
05010015019952017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
BACKGROUND The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective… (More)
  • table 1
  • figure 1
  • table 2
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE We conducted a randomized trial to evaluate the efficacy and safety of intravenous alemtuzumab compared with chlorambucil… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE To test whether eradication of minimal residual disease (MRD) in B-cell chronic lymphocytic leukemia (CLL) by alemtuzumab… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The presence of p53 mutation or deletion predicts for poor response to conventional therapy in chronic lymphocytic leukemia (CLL… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
We report the outcomes after reduced-intensity conditioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Profound T-cell depletion before allotransplantation with gradual posttransplant T-cell repopulation induces a state… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
This study investigated the efficacy, safety, and clinical benefit of alemtuzumab (Campath-1H) for patients with relapsed or… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
This phase II study determined the efficacy and safety of alemtuzumab, a humanized anti-CD52 monoclonal antibody, delivered… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?